Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbCellera Biologics Inc.ABCL · Entity 4118 | Director | June 11, 2026 | June 12, 2026 |
| SomaLogic, Inc.SLGC · Entity 95310 | Director | March 01, 2022 | March 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbCellera Biologics Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2036-06-11 | Direct | 306,633 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 111,701 · Balance 306,633 F1: The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.
SomaLogic, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,430 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 3,430 · Balance 28,430 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2032-02-29 | Direct | 20,600 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 20,600 · Balance 20,600 F1: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 13:03 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 111,701 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0001685889-26-000002 · wk-form4_1781283792.xml · derivative · entry 1 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,633 Underlying: Common Shares · 111,701 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| December 01, 2025 Filed Dec 19, 2025 14:46 UTC | AbCellera Biologics Inc. ABCL · Entity 4118 | GrantShare option (right to buy) · Derivative | 194,932 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001685889-25-000008 · wk-form4_1766173569.xml · derivative · entry 1 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,932 Underlying: Common Shares · 194,932 shares Expires 2035-12-01 F1 · derivative.exercise_date: The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on December 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:16 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 20,600 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001062993-22-006758 · form4.xml · derivative · entry 2 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 Underlying: Common Stock, par value $0.0001 · 20,600 shares Expires 2032-02-29 F1 · shares: 100% of the shares underlying the option vest one year after the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:16 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-006758 · form4.xml · nonDerivative · entry 1 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,430 Read SEC document |
| October 27, 2021 Filed Dec 13, 2021 16:29 UTC | SomaLogic, Inc. SLGC · Entity 95310 | GrantEmployee Stock Option (right to buy) · Derivative | 46,705 | $0.00 Strike: $11.85 | $0.00 |
DisclosureSEC source: 0001062993-21-012746 · form4.xml · derivative · entry 1 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,705 Underlying: Common Stock, par value $0.0001 · 46,705 shares Expires 2031-10-26 F1 · derivative.exercise_date: 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | Exercise / conversionClass B Common Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · derivative · entry 6 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | GrantWarrants to purchase Class A Common Stock (right to buy) · Derivative | 166,666 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · derivative · entry 5 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Class A Common Stock · 166,666 shares Expires 2026-09-01 F3 · kind: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. F3 · price: Following the completion of the Business Combination, warrants to purchase Class A Common Stock become exercisable on October 1, 2021, the date that is 30 days after the closing of the Business Combination. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | GrantClass A Common Stock | 100,000 | $10.00 | $1,000,000.00 |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · nonDerivative · entry 4 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By DeltaXDeltaP Hbar Trust Disclosed balance after: 425,000 F2 · kind: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | GrantClass A Common Stock | 150,000 | $10.00 | $1,500,000.00 |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · nonDerivative · entry 3 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Eleftheria Foundation Disclosed balance after: 325,000 F2 · kind: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | GrantClass A Common Stock | 150,000 | $10.00 | $1,500,000.00 |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · nonDerivative · entry 2 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quake 2018 Charitable Remainder Unitrust Disclosed balance after: 175,000 F2 · kind: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: In connection with the Closing of the Business Combination, 400,000 shares of Class A Common stock were issued and owned directly by Quake 2018 Charitable Remainder Unitrust, The Eleftheria Foundation and DeltaXDeltaP Hbar Trust, respectively (the "Quake Entities"). Mr. Quake has voting and investment discretion with respect to the Class A Common Stock held of record by the Quake Entities. Mr. Quake disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:10 UTC | SomaLogic, Inc. SLGCW · Entity 95310 | OtherClass A Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-046738 · ownership.xml · nonDerivative · entry 1 Quake Stephen · CIK 0001685889 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II Inc. or "CMLS II") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of CMLS II's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.